Alkyl Amines Chemicals Ltd
Incorporated in 1979 by Mr Yogesh Kothari, Alkyl Amines is a leading manufacturer of aliphatic amines in India. Aliphatic amines are products derived from Ammonia (NH3) by displacement of H2 in the Ammonia molecule by other radicals (R) such as Methyl, Ethyl and Propyl.
- Market Cap ₹ 9,451 Cr.
- Current Price ₹ 1,848
- High / Low ₹ 2,115 / 1,212
- Stock P/E 42.0
- Book Value ₹ 300
- Dividend Yield 0.54 %
- ROCE 16.6 %
- ROE 12.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 30.1%
Cons
- The company has delivered a poor sales growth of 4.33% over past five years.
- Company has a low return on equity of 12.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 476 | 484 | 501 | 616 | 846 | 993 | 1,242 | 1,542 | 1,683 | 1,441 | 1,572 | 1,536 | 1,658 | |
| 390 | 393 | 405 | 499 | 682 | 736 | 812 | 1,216 | 1,335 | 1,189 | 1,280 | 1,251 | 1,317 | |
| Operating Profit | 87 | 91 | 95 | 118 | 164 | 257 | 430 | 326 | 348 | 252 | 291 | 285 | 342 |
| OPM % | 18% | 19% | 19% | 19% | 19% | 26% | 35% | 21% | 21% | 17% | 19% | 19% | 21% |
| 2 | 2 | 1 | 2 | 4 | 40 | 6 | 14 | 9 | 14 | 30 | 32 | 33 | |
| Interest | 10 | 8 | 8 | 8 | 15 | 10 | 6 | 3 | 3 | 4 | 1 | 1 | 1 |
| Depreciation | 11 | 13 | 14 | 16 | 23 | 27 | 29 | 35 | 45 | 59 | 71 | 72 | 72 |
| Profit before tax | 67 | 72 | 74 | 96 | 130 | 260 | 401 | 302 | 309 | 202 | 249 | 243 | 302 |
| Tax % | 32% | 31% | 32% | 33% | 36% | 17% | 26% | 26% | 26% | 26% | 25% | 26% | |
| 45 | 50 | 50 | 64 | 84 | 215 | 295 | 225 | 229 | 149 | 186 | 180 | 225 | |
| EPS in Rs | 8.91 | 9.77 | 9.87 | 12.61 | 16.42 | 42.21 | 57.91 | 44.04 | 44.75 | 29.12 | 36.39 | 35.19 | 44.03 |
| Dividend Payout % | 18% | 41% | 20% | 22% | 20% | 19% | 17% | 23% | 22% | 34% | 28% | 28% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 4% |
| 3 Years: | -3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -9% |
| 3 Years: | -8% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | -14% |
| 3 Years: | -8% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 16% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 165 | 189 | 235 | 287 | 355 | 526 | 782 | 980 | 1,159 | 1,257 | 1,392 | 1,523 |
| 135 | 111 | 120 | 181 | 165 | 87 | 47 | 23 | 88 | 3 | 6 | 1 | |
| 93 | 95 | 147 | 159 | 218 | 160 | 306 | 359 | 335 | 314 | 381 | 362 | |
| Total Liabilities | 402 | 406 | 512 | 637 | 749 | 783 | 1,145 | 1,371 | 1,592 | 1,584 | 1,789 | 1,896 |
| 151 | 187 | 220 | 355 | 376 | 423 | 458 | 629 | 719 | 1,089 | 1,044 | 1,015 | |
| CWIP | 31 | 16 | 35 | 18 | 43 | 45 | 138 | 143 | 352 | 36 | 52 | 130 |
| Investments | 2 | 2 | 1 | 1 | 1 | -0 | 30 | -0 | -0 | -0 | -0 | 51 |
| 218 | 201 | 256 | 262 | 328 | 315 | 520 | 600 | 521 | 459 | 693 | 700 | |
| Total Assets | 402 | 406 | 512 | 637 | 749 | 783 | 1,145 | 1,371 | 1,592 | 1,584 | 1,789 | 1,896 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 | 101 | 63 | 102 | 144 | 188 | 364 | 205 | 248 | 275 | 263 | 239 | |
| -31 | -35 | -65 | -132 | -67 | -41 | -213 | -206 | -277 | -121 | -196 | -137 | |
| -36 | -68 | -2 | 32 | -60 | -135 | -86 | -57 | 8 | -140 | -49 | -56 | |
| Net Cash Flow | -6 | -2 | -3 | 2 | 17 | 12 | 65 | -58 | -21 | 13 | 18 | 45 |
| Free Cash Flow | 20 | 66 | -1 | -33 | 75 | 111 | 208 | -41 | -55 | 153 | 216 | 111 |
| CFO/OP | 95% | 128% | 88% | 103% | 109% | 96% | 108% | 86% | 92% | 123% | 108% | 101% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 68 | 71 | 73 | 66 | 60 | 67 | 66 | 56 | 56 | 54 | 55 |
| Inventory Days | 105 | 92 | 165 | 99 | 88 | 67 | 91 | 76 | 82 | 85 | 75 | 57 |
| Days Payable | 58 | 63 | 120 | 78 | 104 | 57 | 133 | 105 | 84 | 85 | 80 | 70 |
| Cash Conversion Cycle | 123 | 96 | 116 | 94 | 51 | 71 | 25 | 36 | 53 | 56 | 48 | 42 |
| Working Capital Days | 93 | 87 | 84 | 76 | 56 | 54 | 26 | 35 | 28 | 47 | 42 | 49 |
| ROCE % | 26% | 26% | 24% | 25% | 29% | 41% | 56% | 33% | 28% | 16% | 19% | 17% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Value (FOB) Rs Lakhs |
|
||||||||||
| R&D Expenditure (% of Turnover) % |
|||||||||||
| Total Permanent Employees count |
|||||||||||
| Revenue Mix - Aliphatic Amines (% of Revenue) % |
|||||||||||
| Revenue Mix - Amine Derivatives (% of Revenue) % |
|||||||||||
| Revenue Mix - Specialty Chemicals (% of Revenue) % |
|||||||||||
| International Presence (Countries Exported To) count |
|||||||||||
| Total Sales Volume tons |
|||||||||||
| Installed Capacity by Site TPA |
|||||||||||
| Overall Capacity Utilization % |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Closure of Trading Window
- Trading window closes from October 1, 2026 for Q2 and half-year unaudited results.
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
- Postal ballot on 5 special resolutions: re-designations of three directors, Rakesh Goyal appointment, and non-executive commission from April 1, 2027.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
May 2026Transcript
-
Nov 2025Transcript REC
-
May 2025Transcript
-
Nov 2024Transcript
-
May 2024Transcript PPT REC
-
May 2024REC
-
Nov 2023Transcript REC
-
May 2023Transcript
-
Nov 2022Transcript
-
May 2022Transcript
-
Nov 2021Transcript
-
Jun 2021Transcript
-
Nov 2020Transcript
-
Jul 2020Transcript
-
Nov 2019Transcript
-
May 2019Transcript
-
Nov 2018Transcript
-
Jun 2018Transcript
-
Nov 2017Transcript
-
Jun 2017Transcript
-
May 2016Transcript
Market Leadership[1] [2]
The company is a global supplier of aliphatic amines, specialty amines, and amine derivatives to the pharmaceutical, agrochemical, water treatment, rubber chemical, and a variety of industries. It holds a leadership position in some of the products in the domestic market.